Presentation is loading. Please wait.

Presentation is loading. Please wait.

Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma  Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia.

Published byAnn-Kristin Didriksen Modified over 5 years ago

Similar presentations

Presentation on theme: "Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma  Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia."— Presentation transcript:

1 Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma 
Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia Simonini, MD, Agnese Vivaldi, PhD, Giovanni Guglielmi, MD, Nicolino Ambrosino, MD, Antonio Chella, MD, Marco Lucchi, MD, Alfredo Mussi, MD, Rudy Foddis, MD  Journal of Thoracic Oncology  Volume 6, Issue 9, Pages (September 2011) DOI: /JTO.0b013e31821e1c08 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Plasma osteopontin (OPN) (A) and soluble mesothelin-related peptides (SMRP) (B) levels in healthy subjects, epithelial MPM patients, and BRD patients. MPM, malignant pleural mesothelioma; BRD, benign respiratory disease. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821e1c08) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Receiver operating characteristic curves in case of predicted probability for pOPN, SMRP, and combination of pOPN and SMRP. The areas under the curves (AUCs) were determined for each marker, comparing healthy subjects and MPM patients. pOPN, plasma osteopontin; SMRP, soluble mesothelin-related peptides; MPM, malignant pleural mesothelioma. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821e1c08) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

4 FIGURE 3 A, Plotted SMRP and pOPN concentrations in healthy subjects and BRD patients. The horizontal dotted line represents the best cutoff for pOPN ( ng/ml) and the vertical dotted line for SMRP (1 nM). B, Linear regression between SMRP and pOPN levels in MPM patients. C, Linear regression between SMRP and pOPN levels in healthy controls and BRD patients. D, Linear regression between SMRP and pOPN levels in all study subjects. pOPN, plasma osteopontin; SMRP, soluble mesothelin-related peptides; BRD, benign respiratory disease. Journal of Thoracic Oncology 2011 6, DOI: ( /JTO.0b013e31821e1c08) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Combined Serum Mesothelin and Plasma Osteopontin Measurements in Malignant Pleural Mesothelioma  Alfonso Cristaudo, MD, Alessandra Bonotti, PhD, Silvia."

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,
Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages 1862-1863.

Massive Bronchogenic Cyst Joseph B. Levin, BA, Chi Wan Koo, MD, Jessica S. Donington, MD Journal of Thoracic Oncology Volume 5, Issue 11, Pages
Volume 119, Issue 4, Pages (April 2001)

Volume 119, Issue 4, Pages (April 2001)
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,

Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.
Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.

Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung.
Epidemiology of Environmental Exposure and Malignant Mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,

Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.

Neoadjuvant Chemotherapy for Stage III and IVA Thymomas: A Single-Institution Experience with a Long Follow-up  Marco Lucchi, MD, Franca Melfi, MD, Paolo.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Epidemiology of Environmental Exposure and Malignant Mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.

The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.
Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.

Biostatistics Primer: What a Clinician Ought to Know—Prognostic and Predictive Factors  Lorinda Simms, MSc, P Stat, Helen Barraclough, MSc, Ramaswamy.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,

Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma  Valentina Pinelli, MD, Sophie.

Pleural Fluid Cytological Yield and Visceral Pleural Invasion in Patients with Epithelioid Malignant Pleural Mesothelioma  Valentina Pinelli, MD, Sophie.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer  Xiaoxia Chen,
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers

Similar presentations

Ads by Google